Leerink, Canaccord Initiate Coverage of HTG Molecular | GenomeWeb

NEW YORK (GenomeWeb) – Leerink Partners and Canaccord Genuity today initiated coverage of HTG Molecular Diagnostics. Leerink gave the firm's shares an "Outperform" rating and an $18 price target while Canaccord gave them a "Buy" rating with a $17 price target.

Canaccord analyst Mark Massaro said in a report that HTG has the opportunity to be a leading player in the approximately $27 billion molecular profiling market, especially for oncology, which he estimated was more than $15 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.